Replimune Group Inc (REPL) - Total Liabilities
Based on the latest financial reports, Replimune Group Inc (REPL) has total liabilities worth $123.05 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Replimune Group Inc to track the company's year-over-year net asset growth rate.
Replimune Group Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Replimune Group Inc's total liabilities have evolved over time, based on quarterly financial data.
Replimune Group Inc Competitors by Total Liabilities
The table below lists competitors of Replimune Group Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
INTEKPLUS Co. Ltd
KQ:064290
|
Korea | ₩85.45 Billion |
|
Echomarketing Co.Ltd
KQ:230360
|
Korea | ₩150.39 Billion |
|
Hubei Mailyard Share Co Ltd
SHG:600107
|
China | CN¥297.65 Million |
|
Shandong Zhangqiu Blower Co Ltd
SHE:002598
|
China | CN¥1.54 Billion |
|
Banvit Bandirma Vitaminli Yem Sanayi AS
IS:BANVT
|
Turkey | TL10.51 Billion |
|
IVF Hartmann Holding AG
SW:VBSN
|
Switzerland | CHF35.56 Million |
|
CapsoVision, Inc. Common Stock
NASDAQ:CV
|
USA | $4.90 Million |
|
Beijing New Universal Science and Technology Co Ltd
SHE:300472
|
China | CN¥1.06 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Replimune Group Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see REPL market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Replimune Group Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Replimune Group Inc (2017–2025)
The table below shows the annual total liabilities of Replimune Group Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $135.49 Million | +19.67% |
| 2024-03-31 | $113.21 Million | +24.00% |
| 2023-03-31 | $91.30 Million | +82.73% |
| 2022-03-31 | $49.96 Million | +12.61% |
| 2021-03-31 | $44.37 Million | -11.93% |
| 2020-03-31 | $50.38 Million | +205.88% |
| 2019-03-31 | $16.47 Million | -82.33% |
| 2018-03-31 | $93.22 Million | +171.51% |
| 2017-03-31 | $34.33 Million | -- |
About Replimune Group Inc
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP… Read more